Overview

This pilot and feasibility study aims to combine recent advances in ultrasound imaging, specifically an endonasal transducer array and contrast enhanced ultrasound, to offer an intraoperative image-guided solution for lesion-specific surgical resection to impact clinical outcome. Should this imaging approach help isolate specific lesions and prevent surgical resection of normal pituitary tissue in this first-in-humans study, then the results will provide clinical data for a much larger multi-center clinical trial.

Eligibility

For Contrast Based Protocol:

Inclusion Criteria:

• Diagnosis of Cushing disease or required resection for non-corticotroph adenomas
• Agree to transsphenoidal resection.

Exclusion Criteria:

• Patients who are unable to consent (or if their legal guardian/representative decline to consent)
• Patients who have known or suspected hypersensitivity to microbubble contrast agents or its components such as polyethylene glycol (PEG).
• Women of child-bearing potential with a positive pregnancy test prior to procedure.
• Patients who have right to left, bi-directional, or transient right to left cardiac shunts.
• Patients who have hypersensitivity to perflutren.

For Non-Contrast Based Protocol:

Inclusion Criteria:

• Patients undergoing any pituitary surgery with the study designated neurosurgeons.
• Patients whose procedures require the use of an intra-operative BK ultrasound without contrast.

Exclusion Criteria:

• Patients who are unable to consent (or if their legal guardian/representative decline to consent)